1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Bristol’s Growth Plans Take A Hit As Cobenfy Fails As A Schizophrenia Add-On

Setback Follows Camzyos Stumble In nHCM

 
• By Mandy Jackson

Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.

Prescribers already treat schizophrenia with combination therapy without approved adjunctive medicines (Shutterstock)
Key Takeaways
  • Bristol’s Cobenfy did not achieve statistical significance on the primary endpoint in the Phase III ARISE clinical trial testing the drug as an add-on to antipsychotic medicines in schizophrenia.
  • Approved in the US as a monotherapy in September 2024, doctors already prescribe Cobenfy in the adjunctive setting for some patients, given the need for additive medicines and long-term practice of combination therapy despite no drug approvals for adjunctive use in schizophrenia.
  • Analysts expect some impact on sales, but most say adjunctive use is likely to continue. Even so, investor confidence in BMS took a hit after the company’s other recent setback for Camzyos.

Bristol Myers Squibb made a $14bn gamble when it agreed to buy Karuna Therapeutics in late 2023 for its drug that was pending US Food and Drug Administration approval at...

BMS announced after the stock market closed on 22 April that its oral M1/M4 muscarinic receptor agonist/muscarinic receptor antagonist did not achieve statistical significance as an add-on therapy on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

More from Scrip

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.